Inhalation of aerosolised medications are the mainstay of treatment for a number of chronic lung diseases and have several advantages over systemically-administered medications. These include more rapid onset of action for drugs such as b-adrenergic agonists when compared with oral medication, high luminal doses for inhaled antibiotics when used to treat endobronchial infection, and an improved therapeutic index compared with systemic delivery for these and other classes of drugs such as corticosteroids. The use of aerosolised drugs to treat patients whose tracheas are intubated is less well established, in part because systemic delivery via the intravenous route can be a simpler alternative for many drugs. Consequently, research in this area is largely limited to a number of in vitro studies and very few clinical trials. Unfortunately, a lack of focus in this area has resulted in a number of practices which at best are ineffective, and at worst dangerous for the patient. Although there have been some attempts to re-invigorate research in order to improve delivery systems, current devices are, to a great extent, based on long-standing technology developed more than 50 years ago. In this review, we explore current knowledge and provide guidance as to when and how the inhaled route may be of value when treating patients whose tracheas are intubated, and we set out the challenges facing those attempting to advance the topic. We conclude by reviewing current areas of interest that may lead to more effective and widespread use of aerosols in the treatment of intubated patients.
Introduction
Inhaled medications are widely used for the treatment of lung diseases in children. There are a number of advantages to delivering drugs by inhalation and these include a much more rapid onset of action for drugs such as b-adrenergic agonists which, when inhaled effectively, cause bronchodilation within minutes rather than hours as happens when they are taken orally. The therapeutic index for a range of drugs such as 'designer' corticosteroids, b-adrenergic agonists and antibiotics such as aminoglycosides is also enhanced by inhalation, with similar efficacy potentially being achieved with a much lower systemic exposure. However, effective inhalation therapy is challenging, with a wide range of variables influencing both the total dose delivered and the distribution of drug within the bronchial tree, such that if not used optimally, little or no drug will reach the smaller airways. In contrast, the oral and intravenous (i.v.) routes will deliver drug to the lungs, potentially providing more uniform distribution, although the proportion of total systemic dose reaching the lungs is lower due to their distribution throughout the whole body.
Currently, the majority of aerosol delivery systems utilise technology that is 60-70 years old, and conspicuously fail to meet modern standards for medical devices as outlined by the Food and Drug Agency (FDA) in the USA [1] . Aerosol delivery systems require multiple steps to be performed correctly in order to ensure drug delivery and inhalation therapy but frequently fail because patients cannot, or will not, use the devices effectively [2] . This is not unexpected, because studies show that healthcare professionals, including doctors, rarely understand the basic concepts of inhalational therapy and are frequently unable to use the devices effectively themselves [3] [4] [5] [6] [7] . Moreover, poor patient adherence to the prescribed treatment of inhalation therapy is similar to other therapeutic modalities.
It is unfortunate that this situation exists for ambulatory patients not requiring respiratory support, despite the publication of numerous reviews, guidelines and educational initiatives [8] and the situation for those requiring respiratory support is at least as challenging. Data on aerosol delivery for patients on respiratory support are limited, with most having been generated using in vitro models. There are few studies assessing drug delivery using radioscintigraphy or pharmacokinetic approaches to assess clinical efficacy or quantify delivery of a drug to the lungs. There are some informative reviews available covering the history and methodology associated with aerosol delivery to intubated and ventilated adult patients [9] , and aerosol delivery in the ventilated paediatric population [10] . Despite these reviews, a wide variety of differing drug delivery practices have been reported [11] [12] [13] , indicating a disconnection between those working in aerosol research and those working in clinical areas. In this article, we review the available literature in order to provide suggestions as to how best to treat individuals requiring a variety of respiratory support. We conducted a literature review initially covering PubMed articles with relevant pre-selected search terms. The current status and areas of research are summarised in Table 1 . In general, the available clinical evidence to support specific therapies is of poor quality, and more research is required in order to improve knowledge in this area.
Is inhaled therapy the best option?
There are many challenges to overcome when using inhaled therapy, not least the fact that if used suboptimally in any setting, little or no drug reaches the intended intended site of action [14] . Alternative delivery routes include i.v., oral or liquid boluses administered via the tracheal tube. In the intensive care setting and the operating theatre, the i.v. route is likely to achieve the most uniform distribution to the lungs. For example, if a patient were to experience significant Table 1 What is known about inhaled drug delivery in children on respiratory support and possible areas of future research.
What is known
• Current approaches to aerosolised therapy are largely based on adapting devices designed to be used by conscious adults.
• Deposition of aerosolised drug becomes increasingly central and heterogeneous as airway obstruction increases.
• Nebulisation remains the only form of aerosolisation available for many drugs, due to lack of other formulations.
• Vibrating mesh nebulisers have low or zero driving gas flow, but drug delivery is still influenced by the device and factors such as where it is placed in the breathing circuit, the size of the tracheal tube and biological secretions within the tubing.
• Pressurised metered-dose inhalers are the simplest delivery system but, as with all systems, drug delivery is highly dependent on the interface between patients and the pressurised metered dose inhalers and may deliver no drug to the patient if used incorrectly.
Possible areas of future research
• Development of novel systems for the delivery of drugs to the lungs of children undergoing short-term and long-term ventilation continues. Many of these focus on specific areas such as delivery of surfactant to non-intubated neonates.
• In vitro studies are of value in determining which delivery systems may prove to be of benefit but coordinated clinical trials are required before clear recommendations can be developed. bronchospasm, i.v. salbutamol is likely to reach the lungs rapidly and, given the safety profile of the drug, it is unlikely to compromise the patient. Similarly, corticosteroids are reliable when given systemically (i.v. or enterally) in children [15] for treating severe exacerbations of asthma. Although inhaled therapy may also be effective if used optimally, there is clear evidence that some inefficient inhalational delivery systems are used, which potentially compromise patient safety.
Despite research into the use of inhaled surfactant for the treatment of pre-term infants [16] , a liquid bolus administered via a tracheal tube remains the principle method of delivery and is very effective [17] . Saline and DNase may be delivered by bolus for the treatment of atelectasis or mucus plugs in combination with physiotherapy in patients whose tracheas are intubated [18, 19] . The liquid bolus approach is not commonly used for other drugs such as antibiotics, even though they are likely to achieve a much higher lung concentration than nebulising the antibiotic into a ventilator circuit. It has been suggested that bolus delivery of salbutamol may be effective than inhaled delivery, probably due to the increased total dose delivered [20] . However, distribution of drug is likely to be uneven compared with aerosolised therapy [21] and much of its effect will be as a result of redistribution within the lungs via the bronchial, as well as the systemic, circulation. For ambulatory patients receiving long-term therapy in the form of continuous oxygen via nasal prongs or non-invasive ventilation, liquid boluses or daily i.v. therapy are not viable options, although some may require intermittent i.v. therapy. Some work has been undertaken to explore drug delivery via nasal cannulae, but this is currently not an option in routine practice.
With regard to inhaled therapy, the advantages of reduced systemic exposure, avoiding the need for i.v. access and ease of delivery in ambulatory patients, such as those with tracheostomies, ensures that the use of aerosols, when used appropriately, will continue to be of value in intubated patients.
Aerosol delivery systems
When an inhaled drug is deemed appropriate for the patient, there are currently three broad classes of delivery systems: pressurised metered-dose inhalers (pMDIs); dry powder inhalers (DPIs), which currently are all patient-actuated; and nebulisers, of which there are a variety of basic types including conventional jet nebulisers, breath-enhanced and vibrating mesh technologies, some of which incorporate electronic control systems.
Pressurised metered-dose inhalers
Traditional pMDIs have remained essentially unchanged since the mid 1950s despite the transition to CFC-free propellants. Although the performance of many hydrofluoroalkane (HFA) propellant pMDIs on the market are essentially identical to that of the older CFC formulations, a number of HFA pMDIs contain a solution rather than a suspension, permitting the generation of aerosols with a significantly lower median mass aerodynamic diameter (MMAD). Although this may improve deposition in the distal airways, the effect may simply be to increase the dose in the gas exchange component of the lungs beyond the conducting airways, and this may actually have an adverse effect on the therapeutic index even when using lower 'nominal' doses. To date, no benefit has been identified from utilising the 'finer' aerosols. To our knowledge, the impact of altering the particle size in this way has not been studied in the context of a patient receiving mechanical ventilatory support. Although they initially appear easy to use, the requirement for good coordination and inhalational technique means few ambulatory patients use them effectively [22] . Although there are a variety of adaptors that allow them to be used in children, their effectiveness varies considerably, with some delivering little or no drug. The pMDIs are relatively cheap, disposable and considered free from concerns regarding contamination [23, 24] . However, they only deliver a limited number of drug classes. One such drug class is bronchodilators and it is estimated that approximately 90% of drugs delivered via aerosol in intubated patients are bronchodilators such as salbutamol [9] . A propellant-free metered-dose inhaler, the Respimat â (Boehringer Ingelheim, Bracknell, Berks, UK) is available, but there are no reports of its use in this context.
Dry powder inhalers
Patient-activated DPIs are not currently used in the context of those receiving ventilatory support, although this is theoretically possible [25] . If powders are to be used in the future, it is likely that patient-independent devices, such as the Exubera (Pfizer, Tadworth, Surrey, UK) device which was developed for inhaled insulin, need development.
Nebulisers
Nebulisers constitute the third type of delivery system for inhaled medications. Modifications have included more 'efficient' venturi devices and dosimetric versions, but the latter are not widely used due to their relatively high cost. A wide range of drugs are available for administration using nebulisers, including antibiotics and drugs used for airway mucosal clearance, such as DNase, mannitol and hypertonic saline. Jet nebulisers require their own driving gas flow, which can be problematic when introduced into nebulising circuits, while vibrating mesh nebulisers may struggle with suspensions and viscous drug formulations. Contamination with microorganisms is a potential issue for all nebulisers, while vibrating mesh nebulisers require cleaning in order to prevent the mesh becoming clogged. The different nebuliser types (jet, ultrasonic and vibrating mesh) have been compared by Fink and Ari [9] . Although inexpensive, jet nebulisers may increase the pressure delivered to the lungs, are relatively noisy and can inactivate proteins within the drug. Vibrating mesh nebulisers are now considered by many to be the nebuliser of choice for ventilator circuits because they do not significantly alter airway pressures, are quiet and generate smaller droplets [26] . If it is not a single-use mesh, it needs to be cleaned carefully in order to prolong the lifespan of the device, because it has a tendency to become clogged after prolonged use, particularly when using drugs in suspension [26] . Although the amount of drug delivered to both awake and ventilated patients is improved when drug delivery is timed with inspiration, newer nebuliser devices have the technology to sense inspiration (adaptive aerosol delivery (AAD)). Examples include the AKITA (Vectura GmbH, Gauling, Germany) and I-neb (Philips Healthcare, Guildford, Surrey, UK) which can reduce drug wastage in the circuit and may provide an additional benefit by recording dosage information [27] [28] [29] . The former utilises conventional nebuliser characteristics with a high driving gas flow, but the latter has not yet been sufficiently adapted. However, this type of technology is likely to be incorporated into future devices.
Patient-related factors influencing drug delivery and distribution within the lungs
Aerosol therapy is most effective in patients with healthy airways, but in those with airway disease, deposition becomes increasingly more central and poorly distributed. This effect is demonstrated by the inverse relationship between lung function and the concentration of antibiotics in sputum after inhalation, the sputum analysed being produced in the larger airways [30] . With non-uniform disease such as localised bronchiectasis, the aerosol is typically deposited in the healthiest areas of the lung [14] . Significant ventilation defects are observed in patients with cystic fibrosis [31, 32] and if gas does not enter these areas then neither will the inhaled drug. The increased volume of purulent sputum in the airways during infective exacerbations further limits drug delivery to the lung peripheries. Hence, the i.v. route continues to be preferred during exacerbations of cystic fibrosis-related lung infection, although inhaled therapy is widely used for maintenance [33] . In asthma, inhaled corticosteroids largely abolish the daily fluctuations in lung function [34, 35] , if taken effectively and > 80% of the time in those with significant disease [36] . The rapidly reversible nature of the disease permits more uniform distribution, because airway obstruction improves following the onset of treatment and hence the inhaled route remains the preferred option for treating these patients.
Impact of respiratory support equipment on drug delivery

Patient interface
In patients whose tracheas are not intubated, upper airway factors will impact on the ability to deliver drugs to the distal airways. Conditions such as significant laryngomalacia, enlarged tonsils and adenoids, micrognathia, macroglossia and, in the acute setting, laryngospasm, all significantly reduce, or prevent, aerosolised particles reaching the lungs. A supraglottic airway device will address some of these problems, but the impact of the device itself on drug delivery has not been formally assessed.
For patients whose tracheas are intubated, the tracheal tube itself influences drug delivery. Previous studies with different sizes of tracheal tubes have shown that the total dose of drug delivered is inversely related to the length of the tube [37] and its internal diameter [23, [38] [39] [40] [41] . It should be noted, however, that the total dose is not the key parameter as small tubes are used when managing small patients and the dose delivered per kg body weight becomes important. Studies attempting to bypass the tracheal tube with catheters have suggested that the impact of the tracheal tube can be reduced by this approach, although this produces its own problems [40] .
External equipment
Therapeutic aerosols generally contain particles with an MMAD between 1 lm and 5 lm that, particularly at the larger end of the range, deposit in the lungs via impaction. Impaction occurs at sites where airflow changes direction, such as at the junction of a T-piece, and is enhanced in the presence of turbulence, such as that generated at points where the diameter of tubing changes and with corrugated tubing. Hence, introduction of devices into ventilator circuits proximal to the tracheal tube and T-piece generally result in reduced delivery. Studies have indicated that drug delivery is enhanced by placing continuous output nebulisers approximately 15 cm proximal to the T-piece, but this is likely due to the intervening tubing acting as a 'holding chamber', as immediately before inhalation it will contain aerosol generated during exhalation. The benefit of introducing a space between nebuliser and T-piece is likely to be lost with dosimetric nebulisers, and the 'optimal' space is likely to be much less with vibrating mesh nebulisers, which do not have a high driving gas flow. Streamlining the design of T-piece connectors can improve drug delivery, as demonstrated by Longest et al. [42] .
Humidification of the circuit also adversely influences drug delivery, presumably although hydroscopic growth of drug particles. Several in vitro studies demonstrated decreased delivered drug doses from nebulisers when humidification was placed within the circuit [43] [44] [45] , as well as in vivo evidence of the same effect in adults inhaling nebulised antibiotics [46] . Moreover, placement of aerosol-generating devices proximal to the humidifier within the circuit results in very limited drug delivery in in vitro models [47] . Despite the known effect of humidification on nebuliser effectiveness, the risk of damaging the patients airway by inhaling dry air and disconnecting the ventilator circuit [9] means that it may be more appropriate to increase the period of treatment with a nebuliser, rather than discontinuing humidification [48] .
pMDI equipment interfaces
A variety of commercially manufactured adaptors exist for pMDI use in intubated patients. These include the Spirale DDS system (Armstrong Medical, Coleraine, Northern Ireland), which includes a collapsible spacer chamber designed to remain in the circuit [49, 50] , a variety of inline spacers from Trudell/Monaghan (Trudell Medical International, London, ON, Canada), a simple pMDI actuator without a chamber that can be introduced into the ventilator circuit (Intersurgical, Wokingham, UK) [51] , and a single swivel tube inhaler (Jackson Allison Medical and Surgical Ltd., Auckland, New Zealand) [52] . There is little in the literature regarding the performance of these devices in clinical practice and no data directly pertaining to children.
An interesting range of 'home-made' devices have also been described in the literature. These include removing pMDI canisters from their housing device and placing them inside a 50-ml syringe, expelling all contents either directly into the tracheal tube or via i.v. tubing down the length of a 4-mm internal diameter tracheal tube [53] or a capnography connector [54] . Not only is there no evidence that such approaches might achieve clinically useful drug delivery, there may also be risks. For example, the off-label use of a Luer lock system in one patient resulted in damage to the device with fragments deposited within the patient's airway [55] . In vitro, 19-G catheters have been used attached to a 60-ml syringe via a Luer lock in order to deliver steroids via pMDI, which allowed more than 50% of the volume of drugs (beclomethasone and triamcinolone) to exit the distal catheter tip [37] . However, in our in vitro laboratory setup, we have found activating the pMDI difficult when inserted into a Luer lock and pilot data indicate limited recovery of drug relative to other methods. During emergency resuscitation, no standard method of pMDI aerosol delivery to counter bronchospasm has been found, and currently used techniques should be considered off-label due to the lack of relevant research into their efficacy in children [9] .
Spacers may be attached directly to the proximal end of the tracheal tube or placed within the breathing circuit. The former appears to avoid loss of the drug within the tubing and T-piece, but the breathing circuit needs to be interrupted in order to introduce and remove the spacer device because it significantly increases dead space. Some spacers have been designed to remain within the breathing circuit, but condensation in the spacer and, more importantly, on the actuator, is a significant problem.
Drug delivery via nasal prongs and non-invasive ventilation
Non-invasive positive pressure ventilation (NPPV), including bi-level positive airway pressure (biPAP) and continuous positive airways pressure (CPAP), is associated with fewer risks compared with more invasive ventilatory support. Data on aerosol delivery strategies using NPPV are limited compared with aerosol delivery during mechanical ventilation, however, many factors that affect aerosol drug delivery during mechanical ventilation are also relevant for NPPV. The major difference with NPPV is the facemask or nasal cannula interface and subsequent exposure of the proximal airway to drugs, which are bypassed during other methods of ventilation, and result in significant proximal airway deposition of drugs [56] . Increasing rates of air flow associated with high-flow nasal oxygen delivery in adults are likely to result in decreased lung delivery of nebulised drugs based on in vitro models, with the fraction delivered being ≤ 10% in all tested cases [57] . In spontaneously breathing, awake patients, nasal delivery may be used in children in order to avoid tracheal intubation, specifically when patients have bronchiolitis. Radiolabel studies in healthy adults report that the use of vibrating mesh nebulisers provide higher lung aerosol deposition compared with jet nebulisers in patients [58] . In a paediatric laboratory model of jet or vibrating mesh nebulisers, use of vibrating mesh nebulisers was superior, although delivery efficiency varies depending on different facemasks [59] . These technologies could be useful for patients during non-invasive ventilation. Recently, clinical trials using a trans-nasal pulmonary aerosol delivery (tPAD) system have begun, and a partnership between the FAVORITE technology and tPAD manufacturers was announced in 2014 [60] .
Special considerations for neonates
In neonates, a lack of relevant clinical drug trials means that most inhaled drug use is off-label, particularly in pre-term infants where there may be long-term health risks [61] . Exogenous lung surfactant is usually administered by liquid bolus directly into the tracheal tube. The delivery of aerosolised surfactant was recently reviewed by Pillow and Minocchieri [62] . Like other drugs, the majority of the pulmonary surfactant administered by aerosol is often retained within the tracheal tube itself, which may be a limiting factor for therapy due to the cost of surfactant and its wastage [61] .
Potential areas that might enhance the role of aerosolised therapy in the acute care setting
Tracheal tube with a distal atomiser
One potential method for improving aerosol drug delivery is to bypass the tubing and produce an aerosol at the distal end of the tracheal tube [63] [64] [65] [66] . The atomiser device invented by Wright and commercialised as the MADett (Teleflex Inc., Morrisville, NC, USA) is one example [65] . Atomisers lack the baffle of a nebuliser and hence generate much coarser aerosols; in the case of the MADett, the manufacturer states that it generates particles in the size range of 30-100 lm which are much larger than the 1-5 lm particles that diffuse effectively through the airways to the peripheral branches, particularly in children. The delivery of surfactant through an inhalation catheter (AeroProbe, Trudell Laboratories, London, Canada) has been examined in vitro, and studies indicate that the use of catheters within the small tracheal tubes required for children may increase pressure within the lung [67] . Liposomes have also been investigated in vitro using the AeroProbe [68] .
Nanoparticles/submicron particles
Theoretically, inhalation of smaller particles may improve their ability to reach distal airways by reducing inertial impaction. Such an effect was suggested in vitro almost 30 years ago, when use of a nebuliser that generated submicron-sized particles improved drug delivery using an in vitro model compared with a conventional nebuliser [69] . The improvement may have been related to the rapid hydroscopic growth of 'conventional' and submicronic particles once introduced into a humid breathing circuit. More importantly, the experimental setup simply provided a one-way flow and did not assess deposition of the drug. Conventionally, the majority of 0.5-lm particles are believed to be exhaled, even when a breath hold is included. Animal work with nanoparticles suggests that particles in the size range of 0.15-5 lm may be more effective at depositing in the distal airways consistent with theoretical modelling (Brownian motion being the principle method of deposition [70] ). It has been proposed that nanoparticles containing iron, when used in combination with a magnetic gradient, might permit targeting and enhance in vivo lung drug delivery [71, 72] . However, these aerosol formulations could present problems with antibacterial defence, including increased growth of bacterial pathogens and inactivation of host defence peptides and proteins [73] , or production of reactive oxygen species that could have cytotoxic effects in lung tissue [74] . To date, no device generating nanoparticles has been developed for inhaled therapeutic purposes.
Patient interfaces
Heliox Goode et al. demonstrated that decreasing gas density, by using a mixture of helium and oxygen, resulted in lowered doses of aerosol within the ventilator circuit but improved delivery compared with air alone [75] . In vitro modelling of airflow suggests that, depending on particle size, heliox may reduce turbulent flow of the aerosol and therefore tracheal deposition [76] . In a randomised, controlled trial of heliox vs. oxygen-based facemask delivery of salbutamol in children presenting to the emergency department with an exacerbation of asthma, significant improvements in short-term respiratory outcomes were observed in the heliox group compared with a control group [77] . With regard to children and tracheal tubes, in vitro research suggests that heliox improves salbutamol delivery [78] , a • May be of greatest benefit in ventilator-associated pneumonia [26, 33] Acute bronchospasm in the operating theatre Tracheal tube or supraglottic airway device
For inhaled therapy pressurised metered-dose inhalers with devices designed to spray the plume bi-directionally or into a low static spacer-like chamber that is in line with the inspiratory airflow For significant bronchospasm in the absence of laryngospasm intravenous b-adrenergic agonist may be a more reliable alternative [8] [9] [10] [34] [35] [36] particle of sufficient MMAD to have reduced turbulent flow as predicted by Katz. Infants with acute respiratory syncytial virus bronchiolitis presenting to the emergency department may have a reduced respiratory distress clinical score, particularly those with more severe disease, if commenced on nasal CPAP, according to a Cochrane review [79] . The relatively high cost of heliox may restrict its use, although further clinical studies are required to demonstrate whether there is a benefit in children.
Conclusion
The evidence for inhaled medications in children presented in this review are summarised in Table 2 .
Despite the widespread use of bronchodilator therapy in patients whose tracheas are intubated, a Cochrane review found no satisfactory clinical trials had been conducted on the use of bronchodilators in intubated and mechanically ventilated patients [80] . Another review of critically ill adults requiring tracheal intubation and bronchodilator therapy concluded that there was insufficient evidence to promote the use of nebulisers or pMDIs for drug administration in ventilated adult patients [81] . There is even less evidence for use in children, despite the burden of respiratory illness in this group of patients. Although there are theoretical reasons that inhaling a medication may be safer and a more effective way of treating pulmonary disease in the intensive care unit and/or operating theatre, the practical difficulties are such that alternative routes continue to be preferred by most clinicians. Some of these difficulties are attributable to problems with simply incorporating a delivery system into a breathing circuit and achieving efficient drug delivery. Technological advances may address many of these issues, but patient-related problems such as laryngospasm, lobar collapse or copious quantities of secretions may still render systemic approaches more effective in many cases.
